NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Olaparib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Glioma; Histiocytosis; Langerhans cell histiocytosis; Liver cancer; Medulloblastoma; Neuroblastoma; Neuroectodermal tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 09 Apr 2018 Planned End Date changed from 30 Mar 2021 to 30 Sep 2024.
- 09 Apr 2018 Planned primary completion date changed from 30 Mar 2021 to 30 Sep 2024.
- 02 Aug 2017 New trial record